Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion

AI Summary

Johnson & Johnson (JNJ) reported Q1 2026 revenue of $24.06 billion, representing a 9.9% year-over-year increase, driven by TREMFYA's growth of 68.3% and DARZALEX's increase of 22.5% to $3.96 billion. The company raised its full-year guidance to a midpoint of $100.8 billion. AbbVie (ABBV) also exceeded expectations with Q1 revenue of $15 billion and a year-over-year increase of 12.4%. AbbVie's Skyrizi reached $4.48 billion with a 30.9% increase, offsetting Humira's 38.6% decline.